Download - ,, p,.c.d.,.dmd.aspetjournals.org/content/dmd/20/6/local/back-matter.pdf · ,, p,.c.d.,. ... c.,
�.4 N�
�-�Jii�1�iiE;iA lucutlv#{149} Diniictoz
R&th.�d� . in � ii
S. � #{176}� �#{176}#{176}-“114d..s O�4.s ii � 14.1. 1 Piicuii ii ii... .4 Turn Auuuw .4 S..4.. M.np.. ii 04.,
966
4,;, St.t.msnt of Ownership.Management and
= Circulation(A.q.4�d by 39 U.S.C. 3686)
IA. T�. �E P,EI�c.s#{246}... I is. �isuc*no.. ,#.o.
DRUG METABOLISM � DISPOSITIOS [� � I �1� �jj �I. F..q....y �l � M. N..41......
&L�)th1v 6
2. D.s. .4 F�
6 � 10192
S. A�u� $.�w�pth�P$.s
$80.00
4. C.s. Mi� Md,... .1 knsw#{248}Oflics .� Pg�icss*, �... Ck�. � � �W+4 C�#{224}J�
429 1. Pr�ton St.z�t, Saltiaor#{149}, MaZI�1aM 21202-3993
L C..�i.s. � Ad*... si ths $.�ns,s Id � �.. OI� .1 b. P�hi... �
429 1. Prstao Stz.1, Mltiaor, Naz�1and 21202-3993
S Fd N.rn.. �M � M.d� Ad*sss �4 � � �d M.�0m. #{163}d.s..(ThN � MUST80Tk �I
p.-. � �jc� �wlllia_ � WLLkin*, 429 1. Preston Stz1, #{163}i1U�r#{149},Nmrjjland 21202-3993
,4�. � _d � �DC. Vincent C. Z�tmon1 , D.pI. of Pharaacology, Un.lv.raity of NlchAgan Pad.lcal School,
lox. Ann *rboc, SI 49109
,. � � � i, � �, � � .� �. � � - �,p.,,,�� � V.� � � 4’ �. � .f�. � b� $.�.dby.� � � � - .,l. 4,..* � k �.. � i � .. � �__4.�,u_.b,_, S,.�w9,�w4) ________________________________
��‘#{176}V iq� rm��sooiocu c/o Ka�j Ctch.r
xo,uI�CiVZ#{227}hI .
,,�N�. c_ M� Ad*...-
S. P.. � by � O�g�WUIl�. A..U.�fliii T� Mid * $�Th� � � � �,I4 � #{149}I� � ... W..
II) �2)c� Hu� N.e Ch.� Owl., N.� chu�d D..mqp,.#{176}#{176}�,.%3 � P..c.� U M...t
j�. � 4NI2 g4� � I.. � � �s � �.d
W.�#d. � .� � ,,� 4.�, � �.
,o. � �d � ii �
�, � - ..w,- �A,�.. N�. CS... LcD. Isc� D..p,.c.d.,.*2 M..wI.�
Ao� N. C.#{216}.. .4 S..1. �P�e4..d NM�� $� F�.#{149} Diii
A. TuiiDi.Ciphii�ii�Dis� 1905 1654
S. Piid sid* Diuuii.d CNc.iius, � �LWm. sd.. � � iid c*fliii. sS..ss .ii.uw. .� .ii�ii .4..
150 82
3. N.j s4..i_..�w �
990 964
C. 744 P44 ..dii, Di�iisisd C�c4ii.44.. 414.1 .� a�Z�
1140 1046
0. Vii. Dii4..#ii. by Mu. Cw* Ouii M.smshi_i. C...isiiy. � Dii. Fvss C.ss
95 98
I. Tii4D.44..4�8..4C�4D#{248} 1225 1144
9.C�NiiD.4*.�I. oo� .�., i.ii .,... �.t � .8.. �
sac szo
z. a.....h� N..#{149} Ai�. �S IONS
0. TOTAl. �.m 46. Fl iidI-4ii4h.spm. � 4... ii Al 1805 1654
II. I #{176}.#{176}‘.‘�-� TN. .4 #{163}4.4..P.iiu4�. � � .,I c.nWy thu 0. st�nss ...d. by
In. ibov#{149} s covi�cl iiid com�l, � �1.d�64c_. 4�2..gm_It�.) Piibllsher
PS Pu.. 3626. i� 101 0.. Miii... ii uw,w) 8Pa14 SuDi, aalh#{149}d b� otb.r ana
967
AUTHOR INDEX
Abbott, Frank S., 45 1, 840
Ackermann, Bradley L., 89Adusumalli, V. E., 530Ag#{252}ndez,J. A. 0., 343Ahlner, Johan, 553Akhtar, M. Humayoun, 356Alderweireldt, F. C., 507Almirez, Ramona, 19Al-Tayib, Yousuf, 889
Alvares, Alvito P., 19
Andersson, K.-E., 148
Aoki, Kimiko, 52Aoki, Syouichi, 541Aoyama, Toshifumi, 566
Arison, Byron H., 869Asbury, Karen J., 616
Axelsson, Krister L., 553
Balani, Suresh K., 869
Baldeck, Jean-Pierre, 603, 802Ball, Simon E., 56
Ballantyne, Bryan, 6Balzarini, Jan, 747Barnes, Stephen, 1 13Barzago, Maria Monica, 826Bates, Theodore R., 572Batt, Anne-Marie, 407Beedham, Christine, 889Beers, Scott A., 47
B#{233}langer, Pierre M., 762Bell, Randy, 328Benet, Leslie Z., 547
Benincosa, Lisa J., 461Benitez, J., 343Benoit, Etienne, 877
Berger, Yves, 316Bertler, Ake, 553Beskitt, Joyce L., 6Bickers, David R., 620Biglino, Giuseppe, 742Blaschke, Terrence F., 379Boal, Jila H., 337Bock,K.W., 137
Boelsterli, Urs A., 96Boger, Robert S., 821Bonati, Maurizio, 826
Bornheim, Lester M., 241Bortolotti, Angela, 826
Bourrie, Martine, 316Bouska, Jennifer, 328Boyer, C. Scott, 863Boyle, Kathleen E., 695Breimer, Douwe D., 502Brendel, Klaus, 802Brewer, C. Fred, 902Britto, Margaret R., 446
Brouwer, Kim L. R., 496, 810
Brown, Nita S., 936Brown, Thomas J., 849Bryan, George T., 559Bundgaard, Hans, 172
Burgio, D., 302Burka, L. T., 643Byrd, Gary D., 192
Cai, Yuli, 432
Cano, Jean-Paul, 316Cantu, Amador R., 360Caputo, Otto, 742Carlin,J.R., 148Carter, George, 328Castonguay, Andre, 510Catalin, Jacques, 316, 578Catlow,J., 102Celardo, Antonio, 826
Cepa, Steven, 328Ceruti, Maurizio, 742Chadwick, Marjory, 198, 436Chakravarty, Prasun K., 281Chandrasurin, Pisal, 679, 920, 928Chang, David, 954
Chang, Jim, 23Chang, Kuo-Mei, 192
Chang, Wen-Chang, 719Chang, Young H., 337
Chen, 1.-Wu, 390, 473, 608Cheng, Haiyung, 596Cheriathundam, Elizabeth, 19Chien, Du-Shieng, 21 1
Chiu, Shuet-Hing Lee, 281Chow, Hsiao-Hui, 288, 432Christians, Uwe, 186, 753Christofalo, P., 148
Chui, Y. C., 840, 941Clarke, J. B., 625
Coffman, B., 896Connors, Suzanne, 802Cook, C. Edgar, 856
Coon, Minor J., 108, 792Cooper, Allen D., 379Corada, Monica, 826
Corcoran, George B., 402Corcos, Laurent, 797Cornpropst, J. David, 849
Coutant, John E., 89Covington, Wendy P., 936Cresteil, Thierry, 877Crysler, C. S., 396CuIp, Hilman W., 849
Damani, L. A., 256
Damani, Lyaquat A., 736Damani, Lyaquatali A., 64Daniels, William D., 849Darbyshire, John F., 566Davis, Carole J., 792Davis, Charles B., 695Davis, Patrick J.,38, 882
Deal, Donna L., 679, 920, 928
deBethizy, J. Don, 192De Clercq, Erik, 747
De Cock Buning, T. J., 507Delatour, Paul, 877
Deleon, Jesus H., 156DeLisa, Anne, 706Deloria, Laurel B., 142Deluna, Florencia A., 428, 608Dewey, R. H., 479Diasio, Robert B., I 13
Diaz, Rolando G., 156
Digenis, G. A., 124
Ding, Xinxin, 792
D’Mello, Anil P., 572Dobbin, P. 5., 256Dommisse, R., 507Donehower, Ross C., 706Dorley, Joan M., 390Doss,GeorgeA., 281
Dueker, Stephen R., 275Duescher, Renee J., 658Duffel, Michael W., 339Duggan, Daniel E., 473
Eddy, A. C., 832Egestad, Bomje, 470
Ehlhardt, William J., 958Elfarra, Adnan A., 658
Ellis, B. L., 256Elsea, Sarah H., 23
Epemolu, Ola R., 736Epemolu, R. 0., 256Eriksson, L.-O., 148
Fabre, Gerard, 316
Farooqui, Mohammed Y. H., 156
Fekete, Tibor, 234Feng, PaulC. C., 616Ferrari, Luc, 407Findlay, John W. A., 679, 920, 928Fischer, Volker, 603, 802
Fisher, Robyn L., 802Fong, Kei-Lai, 396
Fong, Kei-Lai L., 695Franklin, Michael R., 726
Frantz, Stephen W., 6Frydman, Armand, 490
Fujita, Shoichi, 367Fukao, Katashi, 773Fukui, Hiroshi, 585Funae, Y., 79Funae, Yoshihiko, 367
Gallo, James M., 396
Garland, William A., 954Gascon, Marie-Paule, 592
Gatto, Gregory J., 281Ghanayem, B. I., 643
Gibson, G. Gordon, 779Gielen, Jacques E., 407Gillette, James R., 566Glauser, Todd A., 247Gleason, J. G., 479G#{246}ldlin,Christian, 96Goldman, Mark E., 869Gonzalez, Frank J., 566Gooley, Paul R., 665Gordon, W. Perry, 596Granneman, G. Richard, 821
Grant, David F., 779Grau,GeorgesE., 592
Grech-B#{233}banger, Odette, 762Green, M. D., 896
Greene, Jackie M., 192Gregoire, S. L., 148
Gregus, Zolt#{226}n,234, 374Grochow, Louise B., 706Groen, Kees, 502
Grosa, Giorgio, 742Grosse, Christine M., 6Guaitani, Amalia, 826Guengerich, F. Peter, 753Guenthner, Thomas M., 440Gupta, Samir K., 821Guzelian, Philip S., 31
Haggard, K., 948
Hall, Stephen D., 322Hamilton, Marta, 849
Hansen, Kristian T., 172Hanzlik, Robert P., 688Haqqi, Tariq M., 620Harker, W. Graydon, 632
Hasegawa, Takaaki, 653Hashizaki, Man, 816
Hawi,A.A., 124
He, Yan-Ling, 541
Henderson, Laura, 954Hermans, J. J. R., 268Hern#{227}ndez, J. Sergio, 413Hezari, Mehri, 882Hichens, Martin, 608Hider, R. C., 256
Hider, Robert C., 736Higaki, Kazutaka, 350
Hill, Judith M., 856
Hiraoka, K., 226Ho, Chorng-Kei, 337Ho, Dah H., 936Hoener, Betty-Ann, 547Hoffman, Jacob M., 869Hofstra, Angela H., 205Hoglund, P., 148Hollenberg, Norman K., 821Hopkins, William E., 616Hori, Ryohei, 541
Hsieh, Yin-Yi, 719Huang, Jin-Ding, 719
Hunt, Christine, 31Hurowitz, Lisa, 706
Hurst, Gail H., 89Hwang. KinKai, 23
Ibrahim, Safaa S.,47
Ichimura, Fujio, 485, 730Imaoka, S., 79
Imaoka, Susumu, 367Inaba,T., 1,465Ingelman-Sundberg, M., 137
Inui, Ken-Ichi, 541Ishizaki, Junko, 485
Isikawa, Akio, 773
Iwasaki, Youji, 773
Jarman,M., 941
Jaruratanasirikul, Sutep, 379
Jeffcoat, A. Robert, 856Johnson, Randall, 706
Jorquera, Rossana, 510Juchau, Mont R., 218
968 AUTHOR INDEX
Kabow, W., 1, 465Kamimura, Hidetake, 309Kang, Y. James, 714Karisson, Karl-Enk, 262Karnes, H. Thomas, 31Kato, Katsuyoshi, 653
Kato, M., 226Kato, Y., 161Kauffman, Laura R., 869Kaufmann, Scott H., 706
Kawahara, Seiichi, 179Kenna, J. G., 625Kerkvliet, Nancy I., 467Kerremans, Adrian L., 247Khan, Islam U., 620Khokhar, Abdul R., 673
Kido, Yuichiro, 673Kim,HyoJ., 374
Kimura, R., 161King, Joyce D., 869King, Roberta S., 339
Kiss, A. D., 948Kitamura, S., 226
Kitteringham, N. R., 625Kbaassen, Curtis D., 234, 374
Knadler, Mary Pat, 89Kokkonen, P. S., 941
Komura, Hiroshi, 585Koop, Dennis R., 775
Korzekwa, Kenneth R., 566Kraft, Joan Creech, 218Krakoff, Irwin H., 936Kremers, Pierre, 407
Krishna, D. R., 909Kruse,C., 186
Kucharczyk, N., 84, 525, 530, 536Kuo, Be-Sheng, 23Kuritani, Jun, 936Kuroiwa, Yukio, 52Kusmik, William F., 23
Lacarelle, Bruno, 316, 578Ladona, Margarita, 56
Laethem, Carmen L., 775Labande, Marcel, 762Lalka, David, 288
Lam#{233},Michael W., 275Landmesser, Nelson G., 596
Lanens, D., 507Lanzotti, Adriana, 96Larsen, Douglas L., 596Lasker, Jerome M., 241Le Cotonnec, Jean-Yves, 592Levine, Walter G., 902Li,AbbyA., 616Lim, Heng-Keang, 632Li-Muller, S. M. Angela, 205Lin, Jiunn H., 390, 428, 473, 608Linck,A., 186Liu, Mei-Jen, 810
Liu, Tiepu, 1 13Ludeman, Susan, 706Ludeman, Susan M., 337Luengo, A., 343
Lugtenburg, J., 507Luo, Gang, 440Luther, Robert R., 821Lynn, R. K., 479
Maca, B., 330Machinist, Joseph, 328
MacKenzie, Neil E., 665Madhu, Cherukury, 374Madyastha, K. Madhava, 295Magdalou, Jacques, 779Mahadevan, S., 356Mahon, W. A., 465
Mannering, Gilbert J., 142Markham, Peter M., 436Marre, Fran#{231}oise,316Martinet, Michel R., 490Masubuchi, Yasuhiro, 367Matsunaga, T., 79Matsushita, Ryo, 730Maurer, Gerard, 56, 802Mayersohn, Michael, 432McCabe, Francis L., 706McCarthy, M. E., 479McComish, Madeline F., 198McLean, C., 625
McNamara, P. J., 302McNulty, Michael J., 679, 928
Mehta, Mehub, 396Meier, G. P., 832Menon,K.M.J., 108Messing, Edward M., 559Miller, Randall R., 281Minick, Douglas J., 920
Mizutani, Tamio, 816Modi, Raken B., 339Mongan, Amy L., 436Moody, David E., 726, 779
Morn, Dexter, 275Morino, Akira, 585
Morris, M., 84Morris, Marilyn E., 461Mukhtar, Hasan, 620Mulder, G. J., 507Muller, H. J., 507Muraoka, Isao, 653Mutlib, A. E., 45 1, 840
Nabeshima, Toshitaka, 653
Nadai, Masayuki, 653Naesens, Lieve, 747
Nagano, Taizo, 485Nakanishi, Takeaki, 730
Nakano, Masayuki, 179, 350Nakashima, Emi, 485, 730Narimatsu, S., 79Nanmatsu, Shizuo, 367NcNulty, Michael J., 920Nellans, Hugh N., 328
Nelson, Fred R., 679Neumann, Catherine M., 467Newman, Robert A., 936
Newton, J. F., 479
Nicoll-Griffith, D., 383Niessen, W. M. A., 941
Nilsson, Ingemar, 262Noe, Dennis A., 706
Nomeir, Amin A., 198Nomeir, Ann A., 436Norlander, Bj#{228}rn,553
O’Brien, Julie A., 869
Oertbe, Maja, 96
Oesch, Franz, 614Ogata, Hiroyasu, 309
Ohishi, N., 161Ohtsuka, Masaaki, 773
Okumura, Kazuo, 541Olson, Michael J., 518
Otton, S. V., 1
Page, Tanya L., 928Paradysz, Robert T., 695Pare, J. R. Jocelyn, 762
Park, B. K., 625Patanella, James E., 912Patzelov#{226},V., 330Pazdur, Richard, 936Peegel, Helle, 108Peng, Hwei-Ming, 792
Perchonock, C. D., 479Perez-Reyes, Mario, 856
Pernecky, Steven J., 792Petersen, Dennis R., 863Piguet, Pierre-Francois, 592Piguet, Veronique, 490Pink, Jay C., 559Pitzenberger, Steven M., 390, 869
Placidi, Michel, 578Plakas, Steven M., 70Pollack, Gary M., 810Pomerantz, Steven C., 632
Poole, James C., 23Poon,G.K.,941Porchet, Herv#{233}C., 592
PospIiil, J., 330Prueksaritanont, Thomayant, 547Pugh, Dorothy E., 856
Qato, Mazen K., 440Qian, Mingxin, 396
Raber, Martin N., 936Radeke, H. H., 186
Ragner, Jonathan A., 596Rahmani, Roger, 316, 578
Raj, C. Paul, 295Rajaonarison, Jean Francois, 578
Ramjit, Ham G., 869Ramjit, Harry G., 390Rao, M. Sambasiva, 779Rasori,R., 383
Raucy, Judy L., 241Ray, James E., 958Reahal, Satinderpal, 423Reiners, John J., Jr., 360
Remmel, Rory P., 47Rettie, A. E., 832Reznikoff, Catherine A., 559Riviere, Jean-Louis, 877Rodriguez, Rosita J., 962Rooney, Clarence S., 869
Rosegay, Avery, 281Rowinsky, Eric K., 706
Rowlands, M. G., 941Rozman, Peter, 374
Ruenitz, Peter C., 770
Ruzicka, Jan A., 770
Sadeque, A. J. M., 832Sadler, Brian M., 856
Sakai,T., 127
Salazar, Daniel E., 402Sanchez, I. M., 643
Sandri, Rhonda B., 21 1Sarkar, Mohamadi A., 31
Sasaki, Hideki, 585Sato,M., 161
Sattler, M., 186Sattler, Martin, 753
Savina, Paul M., 496
Schaeffer, William H., 130
Schentag, Jerome J., 402Schiebel, H. M., 186SchOller, Alfred, 360Schrenk, D., 137Schuller, Hildegard M., 510
Segall, H. J., 275
Sellers, E. M., 1
Sewing, Karl-Fr., 186, 753Sharer, Jane E., 658Shima, Tomoko, 541Shipley, Lisa A., 849
Shockcor, John, 679, 920Shoeman, Janice A., 142
Siddik, Zahid H., 673Siest, Gerard, 407Silveira, Denise M., 198, 436Singh, S., 256
Singh, Surinder, 736Sipes, I. Glenn, 665
Sjaberg, Per, 470Sladek, N. E., 134Smith, Brian R., 706Smith, John A., 889
Smith, Philip C., 962Smith, Soozy J., 566
Sofia, R. D., 84, 525, 530, 536Sokoluk, Bridget, 120Song, Wei Q., 962
Soong, Seng-Jaw, 113Spanoghe, M., 507
Steams, Ralph A., 281Stehly, Guy R., 70
Steppan, Linda B., 467Straub, K. M., 479
Styczynski, P. B., 896Subrook, Stephen E., Jr., 518
Sugiyama, Katsumi, 566Suzuki, Tokuji, 367Svensson, Craig K., 74Swaffar, Diane S., 632Swagler, Anne R., 396Swaminathan, Santhanam, 559Swanson, S. P., 102Sweeny, David J., 328
Sweet, Edward M., 337
Tajima, Kazuo, 816Takahara, Hiromi, 309Takaori,M., 127Takayasu, Tatsunori, 485Takeda, Masami, 730
Tallant, Marilyn J., 6Tanaka, Einosuke, 773
Tang-Liu, Diane D.-S., 211Tanigawara, Yusuke, 541
Tatsumi, K., 226Taylor, A. M., 148
Tephly, T. R., 896
AUTHOR INDEX 969
Thai, Gerald, 360
Theoharides, Anthony D., 869
Thijssen, H. H. W., 268
Thomsen, Karin F., 172Tilbrook, G. S.,256
Tocco, Dominick J., 428Tomilo, Mark, 74
Torfg#{227}rd,Kristina E., 553Toth, John E., 958Town, Christopher, 954Tracy, Timothy S., 322Trimble, L., 383
Tse, Francis L. S., 603
Turgeon, Jacques, 762
Tyndale, R. F., 1
Uetrecht, Jack P., 120, 205
Umeda, Shin, 367
Urbanski, James J., 695
Usansky, Joel I., 64Utesch, Dietmar, 614
Vadas, Elizabeth, 428
Van Bezooijen, Cornelis F. A., 502Van Der Greef, J., 941
Van de Vyver, F. L., 507Varga, Ferenc, 234Vaz,AlfinD.N., 108
Vedrine, Yves, 490
Veltman, J. C., 948Venkataramana, D., 909Venkataramanan, Raman V., 572
Vickers, Alison E. M., 56, 802Vince, Robert, 47Voyksner, Robert D., 856
Wallach, David, 592Walle, Thomas, 331
Walle, U. Kristina, 331Walsh,JohnS., 912Watanabe, K., 79Watson, R. William G., 413Weber, Gregory L., 665Wedlund, Peter J., 446
Weidolf, Lars, 262
Weinshilboum, Richard M., 247,
413Weller, Stephen, 679Wells, D. A., 124
White, W. Reid, 856Williams, H., 383Wilson, Alan G. E., 616Wilson, Dennis W., 275
Winter, Steven M., 665Wong,J.M.Y.,465Wong, K. K., 84, 525, 530, 536
Wood, Thomas C., 413
Wrigglesworth, John, 423
Wu,D.,l
Yamada, S., 161Yamamoto, I., 79Yamamoto, Kenji, 816Yang, J. T., 84, 525, 536Yang, Shen K., 719
Yang, Wei, 38
Yergey,J., 383
Yokogawa, Koichi, 485Yoo, S. D., 302
Yoshida, H., 127Yoshida, Takemi, 52
Yoshimura, H., 79Yost, Garold S., 632Young, L. M., 840Ythier, Arnaud, 592Yun, Chul-Ho, 753Yuzawa, Kenji, 773
Zamboni, R., 383
Zbaida, Shmuel, 902Zhang, Lisha, 52Zhang, Ruiwen, 1 13Zheng, Jiang, 688
Zhoo, N-S., 134Ziegler, D. M., 948Zimmerman, Cheryl L., 47
Zimmerman, John L., 958Zollinger, Markus, 56
970
SUBJECT INDEX
A-64077, glucuronidation, hepatic microsomes (humans), 328
Abbott-64662, see Enalkiren
Acetaminophen glucuronide, sulfate and, probenecid-impaired biliary
excretion (rats), 496Acetyl CoA:arylamine N-acetyltransferase, H2-receptor antagonists (rats),
74
N-Acetyltransferase, correlation of activities, uroepithelia, in vivo acety-
lator phenotype (humans), 559a1-Acid glycoprotein, plasma proteins, conjugation of dinitrofluoroben-
zene (rats), 625Acitretin, systemic pharmacokinetics (guinea pigs, rats), 21 1Acquired immunodeficiency syndrome
anti-HIV drugs, CD4, pharmacokinetic evaluation (monkeys), 3963’-azido-3’-deoxythymidine drug interactions (humans), 578
Acrivastine, disposition (dogs), 679Acrylic acid, propionic acid and, urinary metabolites, homonuclear 3C
nuclear magnetic resonance spectroscopy (rats), 665
Acyl glucuronide, metabolism of SK&F 102922 (guinea pigs), 479Aging, pharmacokinetic profile oftheophylline, liver (rabbits), 826
Alachlor, metabolism by liver and nasal turbinate tissue (rats, monkeys),
616Albumin
covalent binding ofetodolac acyl glucuronide, 962
plasma proteins, conjugation ofdinitrofluorobenzene (rats), 625Aldehyde dehydrogenase, substrate specificity, liver (mice), 134Aldehyde oxidase, hepatic, metabolism ofcinchona antimalarials (guinea
pigs, rabbits), 889Aldose reductase, inhibitors ALO-4l 14 and ALO-3152, oxidation, cata-
lyzed by liver microsomes (rats), 948
Alendronatepotent antiosteolytic bisphosphonate (rats), 473renal handling (rats), 608
Allylbenzene, 2’,3’-allylic epoxides, hydrolysis, microsomal and epoxidehydrolases (mice, guinea pigs), 440
Amines, tertiary, UDP-glucuronosyltransferases, hepatic microsomes(humans, rabbits), 896
6-Aminocarbovir, pharmacokinetic evaluation as a prodrug, carbovir
(rats), 47
Aminopyrine N-demethylase, caffeine demethylase activity, liver micro-
somes (humans, rats), 343Amphotericin B, disposition (rats), 432
Angiotensin I, pharmacokinetic and pharmacodynamic properties, en-alkiren (humans), 821
Antiarrhythmic agents, glucuronide metabolites of mexiletine, N-oxida-tion and deamination, spectroscopy (rabbits), 762
Antibiotics
hops component colupulone, inducer, hepatic cytochrome P-450 3A
(mice), 142usnic acid, intravenous and oral administration, pharmacokinetics
(rabbits), 909Antiemetic drugs, urinary metabolites of MDL 72,222 (dogs, monkeys),
596Antihypertensive agents, stereoselective disposition ofS-8666, liver prep-
aration (rats), 350Antimalarials, cinchona, role of hepatic aldehyde oxidase, metabolism
(guinea pigs, rabbits), 889Antimicrobial agents, metabolism of sodium nifurstyrenate (rabbits,
guinea pigs, rats, mice, hamsters, fish), 226Antipyrine, theophylline and, metabolism, 3-methylcholanthrene induc-
tion (rats), 502Aryl sulfotransferase IV, hepatic, interactions with N-hydroxy arylamine
(rats), 339Aryl-trifluoromethyl sulfide, specific and enantioselective sulfoxidation,
liver cytochromes P450 (rats), 877
Asthma
aerosolized MK-679, physiological disposition (rats), 428pharmacokinetics and renal handling, enprofylline, pregnancy (rats),
653
Azelastinemetabolism (guinea pigs), 536pharmacokinetics, active metabolite desmethylazelastine (guinea pigs),
530
tissue distribution, lung localization (guinea pigs), 525
3’-Azido-3’-deoxythymidine, drug interactions (humans), 578Azoreductase, microsomal, substrates for, 902
Benz(a)anthracene, fl-naphthoflavone and, induction of CYP1A1mRNA, epidermis and keratinocytes (rats, humans), 620
Benzene
metabolism in hepatocytes, influence ofP-450 2E1 induction, benzenemetabolism (rats), 137
substituted derivatives, inhibition, microsomal cytochrome P-450 2E1-
dependent p-nitrophenob (rabbits), 775Best Paper Award for 1991, 619Bile
metabolite excretion, influence of P-450 2E 1 induction, benzene me-
tabolism (rats), 137metabolites of m-dichborobenzene (rats), 161
probenecid-impaired excretion, acetaminophen glucuronide and sul-
fate (rats), 496Bis(2-ethylhexyl) phthalate, metabolites, glucosidation, new conjugation
pathway, 470Bisphosphonate, antiosteolytic, alendronate (rats), 473Bladder neoplasms, correlation between N-acetyltransferase activities,
uroepithelia, in vivo acetylator phenotype (humans), 559Brain
antagonist of cholecystokinin receptor, physiological disposition, L-365,260 (rats, dogs, monkeys), 390
cytochrome P-450, 446Breast milk, pharmacokinetics ofcaffeine and demethylated metabolites
(rabbits), 302Bromo(monohydroxy)phenyl mercapturic acids, new class of mercap-
turic acids (rats), 688Bunitrolol, 4-hydroxylation, cytochrome P-450 isozyme, liver micro-
somes (rats), 3671 ,3-Butadiene, microsomal oxidation, species and tissue differences
(mice, rats), 6583-tert-Butyl-4-hydroxyanisole, metabolism by horseradish peroxidase,
hydrogen peroxide and, 816
Cadmium, decreased cellular uptake and toxicity, exogenous glutathione,714
Caffeine, demethylated metabolites and, pharmacokinetics, lactatingadult rabbits and neonatal offspring, 302
Caffeine demethylase, activity in liver microsomes (humans, rats), 343Cancer, advanced, pharmacokinetics and pharmacodynamics, topotecan
(humans), 706Carbamoyl, glucuronide conjugate of carvedilol, liver microsomes (dogs,
rats), 130
Carbinolamide, phenolic glucuronide conjugates and, N-methyl-N-(l-methyl-3,3-diphenylpropyl)formamide (rats), 451
Carbon- 13, -labeled xenobiotics, pharmacokinetics, ‘3C-NMR spectros-
copy (rats),507
Carbonyl (phenone)reductase, structure-activity relationship, substrates,liver (humans), 465
Carbonyl reductases, stereoselective acetonyl side chain reduction, war-farm and analogs, 268
Carboviroxidation, liver cytosolic enzymes (rats), 912
SUBJECT INDEX 971
19
pharmacokinetic evaluation, 6-aminocarbovir as prodrug (rats), 47
Carboxyphosphamide, NMR studies of its stability, cell membrane
permeability, 337
Carcinogenesis, metabolism of 4-(methylnitrosamino)-143-pyridyl)-1-butanone, pregnancy and ethanol treatment, liver and lung mi-
crosomes (hamsters), 510Carvedilol, carbamoyl glucuronide conjugate, liver microsomes (dogs,
rats), 130CD4
anti-human immunodeficiency virus drugs, pharmacokinetic evalua-lion (monkeys), 396
metabolically labeled recombinant soluble, intravenous and subcuta-neous administration (rats), 695
Cefoperazone, cephradine and, comparative pharmacokinetics, un-treated streptozotocin diabetic rats, 730
Chinese hamster ovary cells, total body and hepatic clearance, tissue-type plasminogen activator, 541
2-Chboronitrobenzene, 4-chboronitrobenzene and, percutaneous absorp-tion (rats), 436
4-Chloro-5-sulfamoyl anthranilbic acid, microbial models, mammalian
metabolism, 882Cigarette smoking, urinary excretion ofglucuronide conjugates, nicotine,
cotinine and trans-3 ‘-hydroxycotinine (humans), 192Cinchona, antimalarials, role of hepatic aldehyde oxidase, metabolism
(guinea pigs, rabbits), 889Cinobufagin, deacetylation, liver (rats), 52Cocaine
-bioactivating isoform, cytochrome P-4501IB1, hepatic microsomesand hepatocytes (rats), 96
metabolism to norcocaine and N-hydroxynorcocaine, pharmacoki-
netics (mice), 863Coenzyme A
glycine and, limits ofgbycine conjugation in vivo (rats), 234
metabolic inversion of(R)-ibuprofen (rats), 322Coenzyme QlO, tissue concentrations, oral and intraperitoneal admin-
istration (rats), 423Collagen, gels, phenol sulfotransferase activity, liver parenchymal cells
(rats), 614Colupulone, inducer of hepatic cytochrome P-4503A (mice), 142Cotinine, urinary excretion ofglucuronide conjugates, smokers, 192CQA 206-291, N-dealkylation, cytochrome P-450 gene family (humans),
56p-Cresol, metabolic fate of menthofuran (rats), 295Cunninghamella echinulata, biotansformations of N-methylcarbazole,
38Cunninghame/la e/egans, microbial models, mammalian metabolism,
882
Cyanide, in vivo metabolism, methacrylonitrile (rats, mice, gerbils), 156Cyclohexanecarboxylic acid, pharmacokinetics and pharmacodynamics
(rats), 810Cyclophosphamide, ifosfamide and, cytochrome P-450-mediated N-de-
chloroethylation (rats), 770Cyclosporin A, metabolism, liver, kidney and intestine slices (humans,
rats, dogs), 802Cycbosporine, metabolism in liver, low-density lipoprotein, ethinyl estra-
diol (rats), 547CYP1A1, messenger RNA induction, benz(a)anthracene and fl-naphtho-
flavone, epidermis and keratinocytes (rats, humans), 620Cytochrome P450
brain, 446
-dependent activities, interleukin lfl, fetal hepatocytes (rats), 407dominant role in human hepatic microsomal oxidation, l,1,l,2-tetra-
fluoroethane (rats), 5182E2/1A1/1A2, induction by imidazole, neonates (rabbits), 792gene family, N-dealkylation, CQA 206-29 1 (humans), 56genes and subfamilies, phenobarbital and dexamethasone, liver (mice),
797
hepatic and renal, monooxygenases, fuzzy and Sprague-Dawley rats,
isozyme catalyzing bunitrolol 4-hydroxylation, liver microsomes (rats),367
isozymes involved in oxidative metabolism, tetrahydrocannabinol,liver microsomes (rats), 79
liver
enantioselective sulfoxidation, aryl-trifluoromethyl sulfide (rats),877
theophylline metabolism (humans), 31-mediated N-dechloroethylation, cyclophosphamide and ifosfamide
(rats), 770placental aromatase, inhibitors, substituted pyridines (humans), 108
Cytochrome P-4503Acolupulone as inducer (mice), 142enzymes responsible for biotransformation, FK506 and rapamycin
(humans, rats), 753Cytochrome P450 2A2, production of testosterone metabolite, l2a-
hydroxytestosterone, 566
Cytochrome P-450db1, catalytic and immunologic similarities, liver(monkeys, humans), 1
Cytochrome P450 2El-dependent p-nitrophenol hydroxylation, inhibition, substituted ben-
zene derivatives (rabbits), 775influence of induction on benzene metabolism, hepatocytes, biliary
metabolite excretion (rats), 137Cytochrome P-45OIIB1, cocaine-bioactivating isoform, hepatic micro-
somes, hepatocytes (rats), 96Cytochrome P-45011D, subfamily, minaprine 4-hydroxylation, hepatic
microsomes (humans), 316Cytochrome P450 monooxygenase, basal and hydrocarbon-induced,
differential expression, epidermal cells (mice), 360Cytosol
esterases, enantioselectivity, intestinal mucosa (rats), 719liver enzymes, oxidation ofcarbovir (rats), 912stereoselective acetonyl side chain reduction, warfarin and analogs,
268
Debrisoquin, inhibition of clearance in liver, inhibition of dextrome-thorphan, 4-hydroxydebnsoquin (rats, humans), 379
Dehydroepiandrosterone, sulfation of estrone and l7fl-estradiol, liver(humans), 413
Deoxycytidine, analog gemcitabine, metabolism and disposition (mice,
rats, dogs), 849Desmethylazelastine, pharmacokinetics of azelastine (guinea pigs), 530
Dexamethasone, phenobarbital and, cytochrome P-450 genes andsubfamilies, liver (mice), 797
Dextromethorphan, inhibition in liver microsomes, inhibition of debri-
soquin clearance, 4-hydroxydebrisoquin (rats, humans), 379Diabetes, comparative pharmacokinetics, cefoperazone and cephradine
(rats), 730Dibutyryl-cAMP, influence on ibuprofen-induced alterations, sulfate
renal clearance (rats), 461m-Dichlorobenzene, biliary metabolites (rats), 161
6,7-Dichloro-5-(N,N-dimethylsulfamoyl)-2,3-dihydro-2-benzofuran car-boxylic acid, stereoselective renal tubular secretion (monkeys),179
2’,3’-Dideoxycytidine, pharmacokinetic evaluation, CD4, anti-HIVdrugs (monkeys), 396
Diet, deficient intake of sulfur, homeostasis, sulfate and 3’-phosphoad-
enosine 5’-phosphosulfate (rats), 3741,2-Diethyl-3-hydroxypyridin-4-one, pharmacokinetics (rats), 736Dinitrofluorobenzene, conjugation to plasma proteins (rats), 625Diphenyl ether, cleavage of 3-phenoxybenzoic acid, kidney microsomal
preparations (chickens), 356Dipyridine, induction of microsomal epoxide hydrolase, UDP-glucuron-
syltransferase activities (rats), 726Diuretics
stereoselective disposition of S-8666, liver preparation (rats), 350uricosuric, stereoselective renal tubular secretion (monkeys), 179
DuP 753, metabolism in liver slices (rats, monkeys, humans), 281Dyes, substrates for microsomal azoreductase, 902
972 SUBJECT INDEX
Embryo, conceptal retinoid levels, microinjections (rats), 218Enalkiren, pharmacokinetic and pharmacodynamic properties, single
dose study (humans), 821Enflurane, metabolism (dogs), 127Enprofylline, pharmacokinetics and renal handling, pregnancy (rats),
653
Epidermal cells, differential expression, basal and hydrocarbon-inducedcytochrome P450 monooxygenase (mice), 360
Epidermal growth factors, human, pharmacokinetic evaluation (rats), 23Epidermis, keratinocytes and, induction of CYPIA1 mRNA,
benz(a)anthracene and /3-naphthoflavone (rats, humans), 620Epoxide hydrolase, microsomal, UDP-glucuronosyltransferase activities,
induction by dipyridine compounds (rats), 726Epoxide hydrolases, microsomal and cytosolic, hydrolysis, allylic epox-
ides (mice, guinea pigs), 440Ergot, alkaloid CQA 206-29 1 , N-dealkylation, cytochrome P450 gene
family (humans), 56Esterases, microsomal and cytosolic, enantioselectivity, intestinal mucosa
(rats), 719l7fl-Estradiol, estrone and, sulfation, liver (humans), 413Estragole, 2’,3’-allylic epoxides, hydrolysis, microsomal and epoxide
hydrolases (mice, guinea pigs), 440Estrone, 17$-estradiol and, sulfation, liver (humans), 413Ethanol, pregnancy and, NNK metabolism, liver and lung microsomes
(hamsters), 510Ethinyl estradiol, low-density lipoprotein and, cyclosporine metabolism,
liver (rats), 5472-Ethyl-l,3-hexanediol, pharmacokinetics (rats), 6Etodolac acyl glucuronide, covalent binding to albumin, 962Etretinate, systemic pharmacokinetics (guinea pigs, rats), 21 1Eugenol, 2’,3’-allylic epoxides, hydrolysis, microsomal and epoxide hy-
drolases (mice, guinea pigs), 440
Felbamate, metabolism (dogs), 84
Fetus, flavin-containing monooxygenase, stereoselective sulfoxidation(humans), 832
Finasteride, disposition and pharmacokinetics, oral administration (hu-mans), 148
FK506, rapamycin and, cytochrome P450 3A enzymes, biotransfor-mation (humans, rats), 753
Flavin, -containing monooxygenase, stereoselective sulfoxidation (hu-mans), 832
2-Fluoro-fi-alanine, pharmacokinetics and tissue distribution (rats), 113
5-Fluorouracil, toxicity pattern, pharmacokinetics of 2-fluoro-fi-alanine(rats), 113
N-Formylmethamphetamine, carbinolamide and phenolic glucuronide
conjugates, N-methyl-N-(1-methyl-3,3-diphenylpropyl)forma-mide(rats), 451
Ftorafur, uracil and, clinical pharmacology (humans), 936Furfural, furfural alcohol and, comparative metabolism, disposition
(rats), 198Furosemide, N-dealkylation, microbial models, mammalian metabolism,
882
Gemcitabine, metabolism and disposition (mice, rats, dogs), 849
Gentamicin, obesity as risk factor, drug-induced organ injury (rats), 402a-Glucoside, formation of xenobiotics, liver (rats), 309Glucuronide
metabolites ofmexiletine, N-oxidation and deamination, spectroscopy(rabbits), 762
phenolic conjugates and carbinolamide, N-methyl-N-(l-methyl-3,3-diphenylpropyl)formamide (rats), 451
Glutathioneconjugation, metabolic route of omeprazole (rats), 262conjugation of butadiene monoxide, species differences (mice, rats),
658
exogenous, decreased cellular cadmium uptake and toxicity, 714
Glyceryl trinitrate, 1,2-glyceryl dinitrate and 1,3-glyceryl dinitrate, tissuedisposition (rats), 553
Glycine, coenzyme A and, limits to glycine conjugation in vivo (rats),234
Heart, tissue concentrations of coenzyme Q 10 (rats), 423Hepatocytes
benzene metabolism, influence of P-4502E1 induction, biliary metab-olite excretion (rats), 137
cocaine-bioactivating isoform, cytochrome P-45011B1 (rats), 96differential effects of interleukin lfl, cytochrome P450-dependent
activities (rats), 407Hepatomegaly, peroxisome proliferators, commentary on a symposium,
779
High performance liquid chromatography, -atmospheric pressure ioni-zation mass spectrometry, conjugated metabolites, 4-hydroxyan-
drost-4-ene-3,l7-dione, 941Hops, colupulone, inducer, hepatic cytochrome P-4503A (mice), 142
Horseradish peroxidase, hydrogen peroxide and, 3-tert-butyl-4-hydroxy-anisole metabolism, 816
H2-receptor antagonists, liver cytosolic acetyl CoA:arylamine N-acetyl-
transferase (rats), 74Human immunodeficiency virus
anti-HIV drugs, CD4, pharmacokinetic evaluation (monkeys), 396Tat inhibitor Ro 5-3335, disposition (rats, dogs), 954
Human immunodeficiency virus-l, inhibitor L-696,229, metabolism inliver slices (rats), 869
Hydrocarbon, -induced cytochrome P-450 monooxygenase, differential
expression, epidermal cells (mice), 360Hydrogen peroxide, horseradish peroxidase and, 3-tert-butyl-4-hydroxy-
anisole metabolism, 8164-Hydroxyandrost-4-ene-3,l7-dione, conjugated metabolites in urine,
liquid chromatography-atmospheric pressure ionization mass
spectrometry, 941N-Hydroxy arylamine, interactions with hepatic aryl sulfotransferase IV
(rats), 339
trans-3 ‘-Hydroxycotinine, urinary excretion of glucuronide conjugates,smokers, 192
4-Hydroxydebrisoquin, inhibition ofdextromethrophan metabolism, in-
hibition ofdebrisoquin clearance, liver (rats, humans), 379N-Hydroxynorcocaine, metabolism of cocaine, pharmacokinetics (mice),
8634-Hydroxypropranolol, terbutaline and, stereoselective sulfate conjuga-
tion, liver phenosulfotransferases (humans), 3333-Hydroxypyridin-4-ones, 1,2-dimethyl- and 1,2-diethyl-substituted, un-
nary metabolic profiles (humans, rats), 256I 2a-Hydroxytestosterone, testosterone metabolite, production by cyto-
chrome P450 2A2, 566
Ibuprofen, -induced alterations, dibutyryl-cAMP, sulfate renal clearance
(rats), 461(R)-Ibuprofen, metabolic inversion (rats), 322Ictalurus punctatus, disposition of 1-naphthol, 70
Ifosfamide, cyclophosphamide and, cytochrome P450-mediated N-dc-
chloroethylation (rats), 770Imidazole, induction of P-450 cytochromes, neonates (rabbits), 792
Immunosuppression, isolation of rapamycin metabolites (humans), 186Indenesulfonylureas, formation, metabolism ofsulofenur (rats, monkeys,
humans), 958Interleukin 1f3, cytochrome P450-dependent activities, differential ef-
fects, fetal hepatocytes (rats), 407Intestine
cyclosporin A metabolism (humans, rats, dogs), 802mucosa, enantioselectivity, microsomal and cytosolic esterases (rats),
719
Ischemia, liver, trimethadione metabolism, index ofhepatic drug-oxidiz-ing capacity (dogs), 773
Isoniazid, metabolism by activated leukocytes (humans), 2054-[2-(4-Isopropylbenzamido)ethoxy]benzoic acid, enterohepatic circula-
tion (rats),585
Isotretinoin, systemic pharmacokinetics (guinea pigs, rats), 21 1
SUBJECT INDEX 973
Keratinocytes, epidermis and, induction of CYP1A1 mRNA,
benz(a)anthracene and fl-naphthoflavone (rats, humans), 620Kidney
cyclosporin A metabolism (humans, rats, dogs), 802cytochromes P-450-dependent monooxygenases, fuzzy and Sprague-
Dawley rats, 19flavin-containing monooxygenase, stereoselective sulfoxidation (hu-
mans), 832handling of alendronate (rats), 608
microsomes, diphenyl ether cleavage, 3-phenoxybenzoic acid (chick-
ens), 356renal handling and pharmacokinetics, enprofylline, pregnancy (rats),
653
stereoselective tubular secretion, uricosuric diuretics (monkeys), 179
sulfate clearance, ibuprofen-induced alterations, dibutyryl-cAMP
(rats), 461
tissue concentrations ofcoenzyme Ql0 (rats), 423
L-365,260, physiological disposition and metabolism (rats, dogs, mon-
keys), 390L-696,229, metabolism in liver slices (rats), 869Lactation, pharmacokinetics of caffeine and demethylated metabolites
(rabbits), 302Leukocytes
activated, metabolism of isoniazid (humans), 205
comparative metabolism and covalent binding, procainamide (hu-
mans), 120Leukotriene D4, antagonist verlukast, biotransformations (rats), 383
Lichens, intravenous and oral administration, usnic acid, pharmacoki-netics (rabbits), 909
Lipoprotein, low-density, ethinyl estradiol and, cyclosponine metabolism
in liver (rats), 547Liver
aryl sulfotransferase IV, interactions of N-hydroxy arylamine (rats),
339carbonyl (phenone) reductase, structure-activity relationship, sub-
strates (humans), 465clearance of tissue-type plasminogen activator, mouse Cl 27 and CHO
cells, 541
cyclosporin A metabolism (humans, rats, dogs), 802cyclosporine metabolism, low-density lipoprotein, ethinyl estradiol
(rats), 547
cytochrome P450db1, catalytic and immunologic similarities (mon-keys, humans), I
cytochromes P-450
enantioselective sulfoxidation, aryl-tnifluoromethyl sulfide (rats),
877theophylline metabolism (humans), 31
cytochromes P450-dependent monooxygenases, fuzzy and Sprague-
Dawley rats, 19cytosolic acetyl CoA:arylamine N-acetyltransferase, H2-receptor antag-
onists (rats), 74cytosolic enzymes, oxidation of carbovir (rats), 912
deacetylation of cinobufagin (rats), 52drug metabolism enzymes, lack ofeffect, streptogramins (rats), 490enterohepatic circulation, 4-[2-(4-isopropylbenzamido)ethoxy]benzoic
acid (rats), 585
expression of cytochrome P-450 genes and subfamilies, phenobarbitaland dexamethasone (mice), 797
a-glucosidases, a-glucoside formation, xenobiotics (rats), 309inhibition of clearance, inhibition of dextromethrophan, 4-hydroxy-
debrisoquin (rats, humans), 379intravenously injected platinum complex, pharmacokinetics (mice),
673ischemia, trimethadione metabolism, index of hepatic drug-oxidizing
capacity (dogs), 773metabolism of DuP 753 (rats, monkeys, humans), 281
metabolism of L-696,229 (rats), 869nasal turbinate tissue and, metabolism of alachlor (rats, monkeys), 616
parenchymal cells, phenol sulfotransferase activity, collagen gels (rats),614
pharmacokinetic profile of theophylline, different ages (rabbits), 826
phenosulfotransferases, sulfate conjugation, 4-hydroxypropranolol andterbutaline (humans), 333
stereoselective disposition of S-8666 (rats), 350
substrate specificity, novel aldehyde dehydrogenase (mice), 134sulfation of estrone and l7�9-estradiol (humans), 413
Liver microsomes3’-azido-3’-deoxythymidine drug interactions (humans), 578
caffeine demethylase activity (humans, rats), 343
carbamoyl glucuronide conjugate, carvedilol (dogs, rats), 130cocaine-bioactivating isoform, cytochrome P45OIIB1 (rats), 96cytochrome P450 isozyme
catalyzation, bunitrolol 4-hydroxylation (rats), 367oxidative metabolism, tetrahydrocannabinol (rats), 79
effects of pregnancy and ethanol treatment, metabolism, 4-(methylni-trosamino)-1-(3-pyridyl) -1-butanone (hamsters), 510
epoxide hydrolases, hydrolysis, allylic epoxides (mice, guinea pigs),440
flavin-containing monooxygenase, stereoselective sulfoxidation (hu-mans), 832
glucuronidation, NNC 0756 and NNC 0772 (rats), 172
glucuronidation of Zileutron (humans), 328involvement ofcytochrome P4SOIID subfamily, minaprine 4-hydrox-
ylation (humans), 316
metabolism of 7-( 1,3-thiazolidin-2-ylmethyl)theophylline (rats), 742metabolism of monocrotaline (guinea pigs, rats), 275metabolism of tetrahydrocannabinol (humans), 241
oxidation, cytochrome P450, 1,1,1,2-tetrafluoroethane (rats), 518oxidation of aldose reductase inhibitors (rats), 948
substrates for microsomal azoreductase, 902
tertiary amine UDP-glucuronosyltransferases (humans, rabbits), 896thiol methyltransferase, assay conditions, biochemical properties (hu-
mans), 247Lung, localization, tissue distribution, azelastine (guinea pigs), 525Lung microsomes, effects of pregnancy and ethanol treatment, metabo-
lism, 4-(methylnitrosamino)-143-pyridyl)-1-butanone (hamsters),
510Lupus, metabolism of isoniazid, activated leukocytes (humans), 205LY228729, disposition (monkeys, rats), 102
MDL 28,050, metabolism (rats), 89MDL 72,222, urinary metabolites (dogs, monkeys), 596
Menthofuran, metabolic fate (rats), 295Methacrylonitnile, in vivo metabolism to cyanide (rats, mice, gerbils),
156
Methamphetamine, oral, pharmacokinetics, repeated daily dosing (hu-
mans), 856Methylacrylonitrile, disposition, novel exhaled metabolite (rats), 643Methylazoxyprocarbazine, chemical decomposition products, character-
ization (humans), 632N-Methylcarbazole, biotransformations, Cunninghamella echinulata, 38
3-Methylcholanthrene, induction, metabolism, antipynine and theoph-
ylline (rats), 502I-Methyl- 1-cyclohexanecarboxylic acid, pharmacokinetics and pharma-
codynamics (rats), 810
4-(Methylnitrosamino)-1-(3-pyridyl)-l-butanone, effects of pregnancyand ethanol treatment, liver and lung microsomes (hamsters), 510
N-Methylpyrrolidinone, major urinary metabolite (rats), 124Metyrapone, urinary metabolic profile (rats), 64Mexiletine, glucuronide metabolites, N-oxidation and deamination, spec-
troscopy (rabbits), 762
Miconazole, warfarin disposition (rabbits), 572Microsomes
cytosolic esterases and, enantioselectivity, intestinal mucosa (rats), 719epoxide hydrolase, UDP-glucuronosyltransferase activities, induction
by dipyridine compounds (rats), 726liver,see Liver microsomes
974 SUBJECT INDEX
Spleendistribution of 2,3,7,8-tetrachlorodibenzo-p-dioxin (mice), 467
oxidation of 1,3-butadiene, species and tissue differences (mice, rats),658
Milk, pharmacokinetics of caffeine and demethylated metabolites (rab-bits), 302
MK-679, aerosolized, physiological disposition (rats), 428Monocrotaline, hepatic microsomal metabolism (guinea pigs, rats), 275
Monooxygenaseflavin-containing, stereoselective sulfoxidation (humans), 832hepatic and renal cytochromes P450-dependent, fuzzy and Sprague-
Dawley rats, 19
fl-Naphthofiavone, benz(a)anthracene and, induction of CYP1A1mRNA, epidermis and keratinocytes (rats, humans), 620
l-Naphthol, disposition in channel catfish, 70Neonate, induction of P450 cytochromes, imidazole (rabbits), 792Nicotine, urinary excretion of glucuronide conjugates, smokers, 192p-Nitrophenol, cytochrome P450 2El-dependent hydroxylation, inhi-
bition, substituted benzene derivatives (rabbits), 775N-Methyl-N-( 1-methyl-3,3-diphenylpropyl)formamide, carbinolamide
and phenolic glucuronide conjugates (rats), 451NNC 0756, NNC 0772 and, glucuronidation, liver microsomes (rats),
172Norcocaine, metabolism ofcocaine, pharmacokinetics (mice), 863Nose, nasal turbinate tissue and liver, metabolism of alachbor (rats,
monkeys), 616Nuclear magnetic resonance
carbinolamide and phenolic glucuronide conjugates, N-methyl-N-( 1-methyl-3,3-diphenylpropyl)formamide (rats), 451
stability and cell membrane permeability, carboxyphosphamide, 337substrates for microsomal azoreductase, 902
Nuclear magnetic resonance spectroscopy13C, pharmacokinetics, ‘3C-labeled xenobiotics (rats), 507
glucuronide metabolites of mexiletine, N-oxidation and deamination(rabbits),762
urinary metabolites, acrylic acid and propionic acid (rats), 665
Obesity, risk factor in drug-induced organ injury (rats), 402Omeprazole, metabolic route, glutathione conjugation (rats), 262
Osteoporosis, alendronate, potent antiosteolytic bisphosphonate (rats),
473
Peroxisome, proliferators, commentary on a symposium, 779Phenobarbital, dexamethasone and, cytochrome P450 genes and
subfamilies, liver (mice), 797
Phenol sulfotransferaseactivity in liver parenchymal cells, collagen gels (rats), 614liver, sulfate conjugation, 4-hydroxypropranolol and terbutaline (hu-
mans), 333
sulfation of estrone and l7fl-estradiol, liver (humans), 4133-Phenoxybenzoic acid, diphenyl ether cleavage, kidney microsomal
preparations (chickens), 3565-(2-(8-Phenyloctyl)phenyl)-4,6-dithianonanedioic acid, metabolism
(guinea pigs), 4793’-Phosphoadenosine 5’-phosphosulfate, sulfate and, homeostasis, defi-
cient dietary intake of sulfur (rats), 374
9-(2-Phosphonylmethoxyethyl)adenine, pharmacokinetics (mice), 747Placenta, inhibitors of aromatase cytochrome P450, substituted pyni-
dines (humans), 108Plasma, proteins, conjugation of dinitrofluorobenzene (rats), 625
Plasminogen activator, tissue-type, total body and hepatic clearance,mouse C I 27 and CHO cells, 541
Pregnancy
ethanol treatment and, NNK metabolism, liver and lung microsomes
(hamsters), 510
pharmacokinetics and renal handling, enprofylline (rats), 653
Probenecid, -impaired biliary excretion, acetaminophen glucuronide andsulfate (rats), 496
Procainamide, comparative metabolism and covalent binding, leuko-cytes (humans), 120
ProcarbazineBest Paper Award for 199 1, 619
chemical decomposition products, methylazoxyprocarbazine, charac-terization (humans), 632
Propionic acid, acrylic acid and, urinary metabolites, homonuclear 13Cnuclear magnetic resonance spectroscopy (rats), 665
Propranolol, pharmacokinetics and metabolism, influence of vitamin K3(rats), 288
Prough, Russell A., Best Paper Award for 199 1, 619
Pyridines, substituted, inhibitors, placental aromatase cytochrome P450
(humans), 108
Quinine, metabolism ofcinchona antimalarials, role ofhepatic aldehydeoxidase (guinea pigs, rabbits), 889
Quinone, tissue concentrations ofcoenzyme QlO (rats), 423
Quinone reductase, basal and hydrocarbon-induced cytochrome P450
monooxygenase, differential expression, epidermab cells (mice),360
Quinuclidinyl benzylate, physiologically based pharmacokinetic model,
nonlinear tissue binding parameters (rats), 485
RapamycinFK506 and, cytochrome P450 3A enzymes, biotransformation (hu-
mans, rats), 753isolation of immunosuppressive metabolites (humans), 186
Receptorsangiotensin II, antagonist DuP 753, metabolism in liver slices (rats,
monkeys, humans), 281
cholecystokinin, antagonist L-365,260, physiological disposition (rats,dogs, monkeys), 390
dopamine D-1, antagonists NNC 0756 and NNC 0772, liver micro-somes(rats), 172
leukotniene, antagonist SK&F 102922, metabolism (guinea pigs), 479
Renin, inhibitor enalkiren, pharmacokinetic and pharmacodynamicproperties (humans), 821
I 3-cis-Retinoic acid, all-trans-retinoic acid and, conceptal retinoid levels,microinjections (rats), 218
Retinoids, acetylenic, systemic pharmacokinetics (guinea pigs, rats), 21 1Retinol, conceptal retinoid levels, microinjections (rats), 218all-trans-Retinoyl-$-glucuronide, conceptal retinoid levels, microinjec-
tions (rats), 218
Retrovirus, anti-retrovirus agent 9-(2-phosphonylmethoxyethyl)adenine,pharmacokinetics (mice), 747
RNA, messenger, induction ofCYP1A 1, benz(a)anthracene and fi-naph-thoflavone, epidermis and keratinocytes (rats, humans), 620
Ro 5-3335, disposition (rats, dogs), 954
S-8666
stereoselective disposition, liver preparation (rats), 350stereoselective renal tubular secretion (monkeys), 179
Safrole, 2’,3’-allylic epoxides, hydrolysis, microsomal and epoxide hy-drolases (mice, guinea pigs), 440
Serotonin
agonist LY228729, disposition (monkeys, rats), 102
antagonist MDL 72,222, urinary metabolites (dogs, monkeys), 596
antagonist tropisetron, pharmacokinetics, metabolism (humans), 603SK&F 102922, metabolism (guinea pigs), 479Skin
differential expression in epidermal cells, basal and hydrocarbon-induced cytochrome P450 monooxygenase (mice), 360
hepatic and renal cytochromes P450, monooxygenases, fuzzy andSprague-Dawley rats, 19
pharmacokinetics of 2-ethyl-l,3-hexanediol (rats), 6Sodium nifurstyrenate, metabolism (rabbits, guinea pigs, rats, mice,
hamsters, fish), 226Sparteine, metabolites (humans), 330Species differences, microsomal oxidation of 1,3-butadiene (mice, rats),
658
SUBJECT INDEX 975
Zileutron, glucuronidation, hepatic microsomes (humans), 328
intravenously injected platinum complex, pharmacokinetics (mice),
673
Streptogramins, lack of effect, hepatic drug metabolism enzymes (rats),
490Streptozotocin, untreated diabetic rats, comparative pharmacokinetics,
cefoperazone and cephradine (rats), 730Sulfate
3 ‘-phosphoadenosine 5 ‘-phosphosulfate and, homeostasis, deficient
dietary intake of sulfur (rats), 374renal clearance, ibuprofen-induced alterations, dibutyryl-cAMP (rats),
461Sulofenur, metabolism, formation ofindenesulfonylureas(rats, monkeys,
humans), 958
T cells, metabolically labeled recombinant soluble CD4, intravenous andsubcutaneous administration (rats), 695
Terbutaline, 4-hydroxypropranolol and, stereoselective sulfate conjuga-
tion, liver phenosulfotransferases (humans), 333Testosterone, metabolite 12a-hydroxytestosterone, production by cyto-
chrome P450 2A2, 566Tetrachloro(D,L-trans)l ,2-diaminocyclohexane platinum(IV), intrave-
nously injected, pharmacokinetics (mice), 6732,3,7,8-Tetrachlorodibenzo-p-dioxin, distribution in splenic tissue
(mice), 4671,1,1,2-Tetrafluoroethane, dominant role of cytochrome P-450, human
hepatic microsomab oxidation (rats), 518
Tetrahydrocannabinolhepatic microsomal metabolism (humans), 241oxidative metabolism, cytochrome P-450 isozymes, liver microsomes
(rats), 79
Theophyllineantipyrine and, metabolism, 3-methylcholanthrene induction (rats),
502
metabolism, liver cytochromes P450 (humans), 31pharmacokinetic profile, different ages, liver (rabbits), 826
7-( 1,3-Thiazolidin-2-ylmethyl)theophylline, metabolism in liver micro-
somes (rats), 742Thiol methyltransferase, hepatic microsomal, assay conditions, biochem-
ical properties (humans), 247Topotecan, pharmacokinetics and pharmacodynamics, advanced cancer
(humans), 706
Tranquilizers, characterization of xylazine metabolites (rats), 840Tnimethadione, metabolism as index of hepatic drug-oxidizing capacity,
liver ischemia (dogs), 773Triprolidine
disposition and metabolism (mice), 920disposition (dogs), 928
Tropisetron, pharmacokinetics and metabolism (humans), 603
Tumor necrosis factor, binding protein, human urinary tumor, phar-macokinetics (mice), 592
Tweedie, Donald J., Best Paper Award for 1991, 619
UDP-glucuronosyltransferase
hepatic microsomes (humans, rabbits), 896microsomal epoxide hydrolase and, induction by dipyndine com-
pounds (rats), 726Uracil, ftorafur and, clinical pharmacology (humans), 936
Uric acid, stereoselective disposition of 5-8666, liver preparation (rats),350
Urinary neoplasms, tumor necrosis factor binding protein, pharmacoki-
netics (mice), 592Uroepithelia, in vivo acetylator phenotype, correlation, ‘,6’-dimethyl-
phenylamino)-4-oxo-5.6-dihydro-1,3-thiazineN-acetyltransferase
activities (humans), 559
Usnic acid, intravenous and oral administration, pharmacokinetics (rab-
bits), 909
Valproate analogs, pharmacokinetics and pharmacodynamics (rats), 810
Verlukast, biotransformations (rats), 383Vitamin K3, influence on pharmacokinetics and metabolism, proprano-
lol (rats), 288
Warfarin
analogs and, stereoselective acetonyl side chain reduction, 268disposition, effect of miconazole (rabbits), 572
Xenobiotics3C-labeled, noninvasive in vivo ‘3C-NMR spectroscopy (rats), 507
a-glucoside formation, liver, a-glucosidases (rats), 309Xylazine, characterization of metabolites (rats), 840
INSTRUCTIONS TO AUTHORS
Submission of manuscripts. Drug Metabolism and Dis-
position will review in vitro and in vivo experimental
results that contribute significant and original information
on xenobiotic metabolism and disposition. The term xen-
obiotic includes pharmacologic agents as well as environ-
mental chemicals. Pharmacokinetic and pharmacody-
namic manuscripts and those involving mechanisms are
invited. Manuscripts concerned with factors which affect
the biological fate ofchemicals such as genetic, nutritional
or hormonal are of interest. Papers addressing toxicologi-
cal consequences of xenobiotic metabolism are appropn-
ate.
Three copies of each manuscript should be sent to Dr.
Vincent G. Zannoni, Editor, Drug Metabolism and Dis-
position, Department of Pharmacology, University of
Michigan Medical School, MSI, Ann Arbor, Michigan
48109-0626. FAX number: (313)-763-4450. Submission
ofa manuscript implies that the material contained therein
has not previously been published except as an abstract
for a scientific meeting, and that it is not being submitted
elsewhere.
All manuscripts received in the editorial office must be
accompanied either by a check for $40.00 (in U.S. fundspayable to ASPET) or by a validated purchase order form
from the author’s institution. The review process for sub-
mitted manuscripts will be delayed until the manuscript
handling fee or purchase order form is received in the
Editor’s office. If the submission of the manuscript hand-
ling fee entails a personal financial hardship to the au-
thor(s), the manuscript handling fee will be waived. In
that event, the authors should submit a request for waiver
ofthe fee at the time the manuscript is submitted.
If and when manuscripts are accepted for publication,it will be necessary for the American Society for Pharma-
cology and Experimental Therapeutics, Inc., to receive in
writing assignment of copyright from all authors of each
manuscript. The exception would be when the work was
done by employees ofU.S. federal government. The forms
for this assignment will be mailed from the Editorial
Office. Ifthe original copyright belongs to an agency other
than the authors, the assignment form must be signed by
the proper authority, with an attached document indicat-
ing the nature of the copyright agreement.
After Acceptance: When an article has been accepted
for publication, the final manuscript may be sent to the
Editorial Office on diskette. A hard copy must accompany
the diskette. This will expedite the publication process for
Williams & Wilkins.
Authors are encouraged to submit electronic diskettes
of the final version of their manuscripts along with the
typed REVISED manuscript. Diskettes produced on IBM
or IBM-compatible computers are preferred, but those
produced on most Apple/Macintosh or Wang computers
can also be converted. The following word processing
programs are preferred: XyWrite III Plus, Word Perfect4.2, 5.0, or 5. 1 (IBM or Macintosh), Microsoft Word (IBM
or Macintosh), Wang 015 (WPS), and Wordstar (IBM).
Among other word processing systems that we can convert
are CPT 8000, MacWrite 2.2 or 4.5, Display Write 3 or 4,
Multimate, PC Write, Volkswriter, and Write Now. Au-
thors preparing diskettes on Macintosh computers should
not use the Fast Save option. Files in ASCII can also be
used, but are not preferred. Identify the diskette by pro-
vidingjournal name, manuscript number, senior author’s
name, manuscript title, name of computer file, type of
hardware, operating system and version number, and soft-
ware program and version number.
The journal does not assume responsibility for errors in
conversion of customized software, newly released soft-
ware, and special characters. Mathematics and tabular
material will be processed in the traditional manner.
Form and style of manuscript. Manuscripts, in Englishlanguage only, should be typewritten double-spaced with
ample margins, on one side of 8.5 x 1 1-inch pages. The
original typescript and two copies, which may be Xerox
or other good reproductions, or legible carbon copies,
should be sent. All pages should be numbered in sequence,
starting with the title page.
A. Full-length papers should be arranged as follows:1 . Title page, containing the title of the paper, names
of all authors, and the institution(s) where the work was
done. The title should have no footnote numbers (see
Footnotes below). The title should briefly yet explicitly
indicate the contents ofthe paper. Names ofchemicals or
chemical classes studied, species used, etc., should be
included in the title.
2. Running title not exceeding 50 total characters and
spaces. The name and address of the person to whom
editorial correspondence and galley proofs should be sent
should appear at the bottom of this page.
3. Abstract of not more than 250 words.
4. Introduction. A brief summary of the pertinent lit-erature and a statement of the aims of the work.
5. Materials and Methods. Species, strains, sexes, and
ages or sizes of animals, with Latin names where required
for distinction, should be given. Sources and purities of
chemicals other than common reagents should be mdi-cated. Equipment used and conditions of use should be
specified. When published methods are used, a biblio-
graphic reference is sufficient; minor modifications should
be described. When a method has been extensively mod-
ified, the entire new procedure should be described. Au-
thors should attempt to describe their work in all cases so
that their peers would be able to repeat the experiments.
Where conditions for similar experiments vary throughout
the work, these may be indicated in legends to figures and
tables. Properties and proof of structure must be given forreference compounds used for metabolite identification.
6. Results. These should be presented as much as pos-sible in graphic and tabular form. When, however, a table
would include only two or three values, it may be prefer-
able to present the data in sentence form in the text.
Authors should avoid using several tables describing very
similar experiments; these should be combined whereverpossible, unless this would result in overcomplicated, un-
wieldy tables. The same data should normally not be
repeated in tables and figures. The text should be used to
describe and summarize the data and to draw primary
conclusions from them, but not to repeat the numerical
data. No extended discussion of the results should be
included in this section.
7. Discussion. The major conclusions to be drawn from
the work should be assembled here, and these should be
discussed with respect to the existing body of knowledge
in the immediate area. Graphic schema should be used
wherever possible to clarify the conclusions. Speculation
should be clearly identified as such, and should be germane
to the data presented. Questions raised by the work, or
those inherent in the experiments, should be discussed.
Although it is normally preferable to separate the Re-
sults and Discussion sections, these sections, e.g. , when an
extended discussion ofsome ofthe experiments is required
for an understanding of subsequent experiments, may
have to be combined occasionally.
8. Acknowledgments oftechnical assistance, gifts of ma-
terials, and other aid. Financial support should not be
mentioned here, but rather in an unnumbered footnote to
the title (see Footnotes, below).
9. References, numbered in order ofcitation in the text.
Examples of style of references follow:
1 . S. S. Lau, G. D. Abrams, and V. G. Zannoni: Metabolic
activation and detoxification of bromobenzene leading
to cytotoxicity. I Pharmacol. Exp. Ther. 214, 703-708(1980).
2. T. C. Butler: The distribution ofdrugs. In “Fundamen-
tals of Drug Metabolism and Drug Disposition” (B. N.
La Du, H. G. Mandel, and E. L. Way, eds.), pp. 44-
62. Williams & Wilkins, Baltimore, 1 97 1.
Papers that have actually been accepted for publication
may be cited among the references; give authors, journal
name, and the words “in press.” Work not published or
accepted, or personal communications, should be cited by
footnote. Where knowledge ofunpublished work is crucial
to evaluation of a paper, duplicate copies of the pertinent
data should be submitted with the manuscript for exami-
nation by the referees.
Authors are urged to exercise the utmost care that
references are accurate. As a rule, references should not
be included that have not been examined personally by
the author. When, because of its rarity of language, the
primary reference could not be examined, the secondary
source should be indicated as well, as follows:
4. K. Maemoto, N. Seike, and M. Hirata, Kobunshi Ka-
gaku 15, 660 (1958); Chem. Abstr. 54, 14775 (1960).
References should be cited in the text by numbers within
parentheses. Abbreviations of journal names should be
those given in Index Medicus.
10. Footnotes, presented in the following order:(a) Unnumbered footnote giving source of financial
support, thesis information, citation of abstracts of meet-
ings where this work was presented, etc., and, in a separate
paragraph, the name and full address (with street address
or P.O. box where applicable, and zip code number) of
person to receive reprint requests.
(b) Numbered footnotes, starting with those (if any) to
authors’ names. Number footnotes in sequence through-
out the text, using superscript numbers.
1 1 . Tables, each on a separate page. Tables are to be
numbered with arabic numbers. The title should be in
italics (or underlined) with only the first word and proper
names capitalized. General statements about the table
should follow the title in paragraph form. Footnotes to
the table should be indicated by italicized lower case
superscript letters, starting with a for each table. Footnotes
should be typed immediately below each table.
1 2. Legends for figures. Figures should be numbered
with arabic numbers, followed by the title in italics (or
underlined), with only the first word and proper nouns
capitalized. The remainder of the explanatory material
should be in paragraph form below the title.
1 3. Index terms. A list of index terms which may be
used in constructing the annual index should constitute
the last typed page of the manuscript.
14. Figures should be submitted with the original
typescript as unmounted glossy photographic prints no
larger than 8 x 10 inches (20 x 25 cm). Xerox or other
good reproductions of line prints may accompany the
other two copies of the manuscript; in the case of half-
tone material, three photographic prints should be sent.
Letters, numbers, and symbols must be large enough to
be readily legible after reduction to single-column size;
these should be at least 1 .5 mm high after reduction. The
style of figures should be uniform throughout the paper.
Figures should be simple and uncluttered, so that they are
readily understandable- after reduction in size. Thus, in
line graphs with multiple lines, it is usually preferable to
use different symbols for the experimental points for dif-
ferent lines, with the explanation ofsymbols in the legend,
rather than to attempt to label individual lines. Abscissa
and ordinate should be clearly labeled with scale, name,
and dimensions of quantities expressed.
B. Short Communications. Short Communications
should not be divided into the sections appropriate for full
papers and should not contain more than 1000 words.
However, they are subject to the same review process as
are full papers. No abstract is required. The first paragraph
should give an introduction to the work. The experiments
and results should be described in narrative fashion. A
moderate amount oftabular and graphic material may be
presented, but the total space allotted to a Communication
may not exceed three printed pages. Structural formulae
of parent compounds and metabolites should be given;
where possible, these should be general formulae with
variable groups identified in a legend.
Title, authors’ names and affiliations, footnotes, cap-
tions, legends, references, and index terms should follow
the forms outlined above for full papers.
C. Reviews. Occasional brief reviews will be published,covering rather limited aspects of a subject in the area of
interest of this journal. These may most typically be
critical reviews that present the author’s view ofthe current
state of the subject, or prospective articles intended to
stimulate discussion and research.
D. Letters. Letters to the editor are invited, in which
relevant work described in this or other journals is dis-
cussed, interesting points raised as suggestions for further
work, or new interpretations ofexisting data made. Where
appropriate, authors of papers to which reference is made
will be invited to reply. Letters presenting new data will
not normally be accepted.
E. National Auxiliary Publications Service (N.A.P.S.).In some cases, results of investigations may be of archival
value, but present insufficient new information of general
interest to the scientific community in terms of method-
ology, types of pathway, significant species differences,
interrelationships with other pharmacologic or toxicologic
properties, etc., to warrant publication in extended form.For deposit with the National Auxiliary Publications Serv-ice (N. A. P. 5.), the data must be submitted in triplicate
with the manuscript. The original copy for the documen-
tary material will be deposited with N. A. P. S. and theaccession number will be published.
Abbreviations for units of measurement should be Un-punctuated, with no distinction between singular and
plural forms. Multiples of units should be indicated as
follows: kg, g, mg, �g (not ug, mcg, or ‘y), ng, pg. Abbre-
viations to be used for units of measurement are:
Mass: g (gram); mol (mole); eq (equivalent). Do not use
M as an abbreviation for mole, as M is used solely as the
concentration term molar.Concentration: M (molar); N (normal); % (percent). In
the latter case, the basis offormulation should be indicated
as % (w/w), % (w/v), or % (v/v) to signify g/ 100 g, g/ 100ml, or ml/lOO ml. The term mg% should not be used.Mixtures should be shown as, for example: acetone/0.5 MKCI/glacial acetic acid, 1:5:2 (v/v).
Length: m (meter); j�m (micrometer). Where commonusage dictates, A (Angstrom) may be used.
Volume: liter should be spelled out, to avoid confusionwith the numeral 1 . Abbreviate compound words contain-
ing the root liter, as ml, �sl, etc.Time: hr (hour); mm (minute); sec (second). Days and
longer units of time should be spelled out.
Radioactivity: Ci (curie); r (roentgen); cpm or dpm
(counts or disintegrations per mm).Electricity: V (volt); amp (ampere); Hz (cycles/sec).
Spectrometry: A#{231}� [absorbance (not OD or E) at 000nm (not m�t) wavelength]; e (molar absorption coefficient,
with units M cm); UV (ultraviolet); IR (infrared); ESR
(electron-spin resonance); NMR (nuclear magnetic reso-
nance); t5 [chemical shift, with units ppm (parts per mu-
lion)]; s (singlet); d (doublet); t (triplet); m (multiplet);
amu (atomic mass units); m/z (mass/charge ratio).
Chromatography: TLC (thin-layer chromatography); RF(retardation factor); GLC (gas-liquid chromatography); RT
(retention time); GC/MS (coupled gas chromatography-
mass spectrometry); HPLC (high-pressure liquid chroma-
tography).
Equilibrium and kinetic constants: Kd (dissociation con-
stant); IC or K, (dissociation constant of enzyme-substrateor enzyme-inhibitor complex); KM (Michaelis constant);
Vmax (maximum initial velocity); k (rate constant); pK,�
(negative logarithm of acidic dissociation constant); t112,
half-life; AUC, area under the curve ofplasma concentra-
tions vs. time.
Statistics: p (probability of chance observation); N
(number of experiments); SD (standard deviation of the
series); SE (standard error of the mean).
Other abbreviations: #{176}C(degrees of temperature); g (ac-celeration due to gravity, as in 9000g); rpm (revolutions
per mm); LD50 and ED50 (median lethal and effective
doses); iv (intravenous); ip (intraperitoneal); im (intra-
muscular); sc (subcutaneous); po (peroral); m.p. (melting
point); sp.g. (specific gravity).
Drugs and chemicals: The following abbreviations may
be used without definition: NAD�, NADH, NADP�,NADPH, FMN, FAD, ATP et al., RNA, DNA, UDP-
glucuronic acid, Tris, EDTA; SKF 525-A; all other abbre-
viations should be explained in a single footnote at the
point ofuse ofthe first one. Cytochromes should be named
as follows: cytochrome b5, cytochrome c, cytochrome P-
450. Generic names of drugs should be used; the trade-
name, capitalized, may be given in parentheses after the
first use of the generic name. Where no generic name
exists, a code number may be used, but the full chemical
name of the compound must be given in parentheses
following the first use of the number. Trade-names and
code numbers should not be used in the title.
The composite character of drugs which are mixtures
of stereoisomers must be brought to the attention of the
reader. The prefix rac-, e.g. rac-propranolol, in the case of
racemates, and (Z/E)- or cis/trans- in the case ofthat typeof isomer is obligatory. The implications of the composite
nature of the drugs studies for the interpretation of the
data measured and the conclusions drawn must be made
explicit.
Page charges: authors are assessed page charges at the
rate of$30 per printed page. With the galley proof, authors
will receive a request for page charges. These charges will
be assessed unless they involve personal financial hard-
ships to the authors. Payment of the charge is not a
condition for publication. Neither the editors nor review-
ers know who has paid the charge.
DRUG METABOLISM AND DISPOSITION
Vincent G. Zannoni, Editor
Robert L. Susick, Jr., Associate EditorMichele Kranick and Tern Kisner, Assistants to the Editor
Editorial Advisory Board
Alvito P. Alvares Charles T. Gombar Gary PollackGhulan A. S. Ansari David W. Hem Russell A. Prough
John R. Bend Aziz Karim Louis RadulovicJudy L. Bolton Dennis R. Koop Lora E. RikansMichael J. Brabec Arun P. Kulkarni Paul H. SatoJoanne Brodfuehrer Bert N. La Du William H. SchaeferJohn Caldwell Serrine S. Lau Don W. ShoemanArthur K. Cho Gerald A. LeBlanc Robert C. SmartAlan B. Combs Walter G. Levine Philip C. SmithC. Edgar Cook Fedor Medzihradsky Elliot S. VesellEdward Domino Joseph N. Miceli Mary Vore
Kenneth H. Dudley Terrence J. Monks William J. WaddellDeanne M. Dulik Hasan Mukhtar Thomas WalleHarry W. Eckerson Catherine M. Neumann
Board of Publications Trustees
Kenneth E. Moore, Chairman Marlene L. Cohen Marcus M. ReidenbergArthur J. Atkinson, Jr. T. Kendall Harden Robert E. StitzelWilliam A. Cattenall John A. Harvey Vincent G. Zannoni
Horace Loh
Executive Officer
Kay A. Croker
VOLUME 20
1992